LILY OF THE VALLEY
FOR HOMOEOPATHIC PREPARATIONS

CONVALLARIA MAJALIS
FOR HOMOEOPATHIC PREPARATIONS

Convallaria majalis ad praeparationes homoeopathicas

DEFINITION

Whole, fresh, blooming plant, Convallaria majalis L.

CHARACTERS

Macroscopic and microscopic characters described under identification tests A and B.
Characteristic odour.

IDENTIFICATION

A. Perennial herb with creeping rhizome bearing numerous rootlets. Stem 10 cm to 20 cm high with
at the base 2 amplecant leaves, curvinervate, lanceolate-oval, about 4 cm large on 10 cm to 15
cm long. Inflorescence in unilateral raceme at the tip of the bare stalk. White, globular bell-
shaped flowers with 6 curved teeth, 6 stamens, 3-carpel ovary topped by a short style.

B. Take a sample of epidermis from the underside of a leaf of lily of the valley. Examine under a
microscope, using chloral hydrate solution R. Stomatiferous abaxial epidermis; elongated
epidermis cells, more or less rectangular to parallelepipedic measuring about 100 µm long and
25 µm large; numerous stomata surrounded by four subsidiary cells (similar to the other
epidermis cells), two are placed on either side of the stomata parallel to the ostiole, the other two
are located at each end of the stoma.

TESTS

Foreign matter (2.8.2): maximum 5 per cent.

Loss on drying (2.2.32): minimum 70.0 per cent, determined on 5.0 g of finely-cut drug, by drying
in an oven at 105 °C for 2 h.

STOCK

DEFINITION

Lily of the valley mother tincture complies with the requirements of the general technique for the
preparation of mother tinctures (see Homoeopathic Preparations (1038) and French Pharmacopoeia Authority Supplement). The mother tincture is prepared with ethanol (65 per cent V/V), using the whole, fresh, blooming plant, Convallaria majalis L.

The General Chapters and General Monographs of the European Pharmacopoeia and Preamble of the French Pharmacopoeia apply.

French Pharmacopoeia 2007
Content: minimum 0.040 per cent m/m of cardenolic heterosides, expressed as digitoxin (C_{41}H_{64}O_{12}; M_r 765).

CHARACTERS

Appearance: greenish-brown liquid.

IDENTIFICATION

A. Thin layer chromatography (2.2.27).

Test solution. Mother tincture.

Reference solution. Dissolve 10 mg of aescin R and 10 mg of asiaticoside R in 10 mL of methanol R.

Plate: TLC silica gel plate R.


Application: 50 µL, as bands.

Development: over a path of 10 cm.

Drying: in air.

Detection: spray with a 100 g/L solution of sulfuric acid R in ethanol (96 per cent) R. Heat at 100-105 °C for 10 min. Examine in daylight.

Results: see below the sequence of zones present in the chromatograms obtained with the reference solution and the test solution. Furthermore other faint zones may be present in the chromatogram obtained with the test solution.

<table>
<thead>
<tr>
<th>Top of the plate</th>
<th>Reference solution</th>
<th>Test solution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aescin: a purplish-grey zone</td>
<td>A purplish-pink zone</td>
<td>A greyish-brown zone</td>
</tr>
<tr>
<td>Asiaticoside: a grey zone</td>
<td>A grey zone</td>
<td>One to two more or less isolated brown zones</td>
</tr>
</tbody>
</table>

B. Thin layer chromatography (2.2.27).
Test solution. Heat 10 mL of mother tincture to the boiling point for 2 min with 5 mL of lead acetate solution R. After cooling, centrifuge the mixture. Shake the supernatant with 15 mL of methylene chloride R. Collect the organic solution and dry it on anhydrous sodium sulfate R. Filter on cotton plug. Evaporate on a water-bath. Dissolve the residue in 1 mL of ethanol (70 per cent V/V) R.

Reference solution. Dissolve 2 mg of convallatoxine R and 5 mg of digitoxin R in 10 mL of methanol R.

Plate: TLC silica gel plate R.


Application: 40 µL, as bands.

Development: over a path of 10 cm.

Drying: in air.

Detection: spray with a 10 g/L solution of dinitrobenzoic acid R in a mixture composed of equal quantities of methanol R and potassium hydroxide 2 M. Examine in daylight.

Results: see below the sequence of zones present in the chromatograms obtained with the reference solution and the test solution. Furthermore other faint zones may be present in the chromatogram obtained with the test solution.

<table>
<thead>
<tr>
<th>Top of the plate</th>
<th>Reference solution</th>
<th>Test solution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Digitoxin: a purple zone</td>
<td>A purple zone</td>
<td>A purple zone</td>
</tr>
<tr>
<td>Convallatoxine: a purple zone</td>
<td>A purple zone (convallatoxine)</td>
<td>A purple zone</td>
</tr>
</tbody>
</table>

TESTS

Ethanol (2.9.10): 60 per cent V/V to 70 per cent V/V.

Dry residue (2.8.16): minimum 2.0 per cent m/m.

ASSAY

Ultraviolet and visible absorption spectrophotometry (2.2.25).

Prepare simultaneously the reference solution and the test solution.

Test solution. In a round-bottomed flask, place 2.5 g of mother tincture accurately weighed, add 50.0 mL of water R then 5.0 mL of a 150 g/L solution of lead acetate R. Shake for some min, add 7.5 mL of a 40 g/L solution of disodium hydrogen phosphate R. Filter. Add 5 mL of 150 g/L hydrochloric acid R to 50.0 mL of the filtrate and heat under a reflux condenser on a water-bath for 1 h. Transfer into a separating funnel, rinse the round-bottomed flask twice with 5 mL of water R.

The General Chapters and General Monographs of the European Pharmacopoeia and Preamble of the French Pharmacopoeia apply.

French Pharmacopoeia 2007
and shake 3 times with 25 mL of methylene chloride R. Combine the organic layers, dry them on anhydrous sodium sulfate R and dilute to 100.0 mL with methylene chloride R. Evaporate to dryness 40.0 mL of the organic solution. Dissolve the residue in 7.0 mL of ethanol (50 per cent V/V) R then add 2.0 mL of dinitrobenzoic acid solution R and 1.0 mL of sodium hydroxide 1 M.

**Reference solution.** Dissolve accurately 50.0 mg of digitoxin CRS in 50.0 mL of ethanol (96 per cent) R. Take 5.0 mL of this solution and dilute to 50.0 mL with ethanol (96 per cent) R. Take 5.0 mL of this solution. Add 25 mL of water R and 3 mL of 150 g/L hydrochloric acid R. Heat under a reflux condenser on a water-bath for 1 h. Transfer into a separating funnel, rinse the round-bottomed flask twice with 5 mL of water R and shake 3 times with 25 mL of methylene chloride R. Combine the organic layers, dry them on anhydrous sodium sulfate R and dilute to 100.0 mL with methylene chloride R. Evaporate to dryness 40.0 mL of the organic layer solution. Dissolve the residue in 7.0 mL of ethanol (50 per cent V/V) R then add 2.0 mL of dinitrobenzoic acid solution R, and 1.0 mL of sodium hydroxide 1 M.

**Compensation liquid.** Mix 1.0 mL of sodium hydroxide 1 M, 2.0 mL of dinitrobenzoic acid solution R and 7.0 mL of ethanol (50 per cent V/V) R.

Repeat the measure of the absorbance of the solutions over the first 12 min at 540 nm, until the maximum is reached in comparison with the compensation liquid.

Calculate the percentage content m/m of cardenolic heterosides, expressed as digitoxin, from the expression:

\[
\frac{A_1 \times m_2 \times 1.25}{A_2 \times m_1}
\]

- \(A_1\) = absorbance of the test solution,
- \(A_2\) = absorbance of the reference solution,
- \(m_1\) = mass of the mother tincture sample, in grams,
- \(m_2\) = mass of digitoxin sample in the reference solution, in grams.

**The General Chapters and General Monographs of the European Pharmacopoeia and Preamble of the French Pharmacopoeia apply.**

**French Pharmacopoeia 2007**